Sign up to our newsletter Subscribe
Analysing Global Immunisation Expenditure

Sign up to our newsletter Subscribe
This OHE Seminar Briefing recounts a presentation by Prof Henry Grabowski on US Priority Review Vouchers, intended to provide an incentive for the development of drugs for tropical diseases. One of the originators of the idea, he recounts the history…
This OHE Seminar Briefing recounts a presentation by Prof Henry Grabowski on US Priority Review Vouchers, intended to provide an incentive for the development of drugs for tropical diseases. One of the originators of the idea, he recounts the history of its development and examines the potential impact of PRVs.
Priority Review Vouchers (PRVs) are awarded in the US to companies that gain approval there for one of sixteen tropical diseases, under a law passed in 2007. The PRV entitles the holder to priority review by the FDA of another drug of the bearer’s choice. The Vouchers are transferable, not limited to use by the company that gained approval of the neglected-disease drug.
This Seminar Briefing recounts a presentation by Prof Henry G Grabowski, one of the originators of the idea of PRVs. It includes:
Download Grabowksi, H.G. Priority Review Vouchers to encourage innovation for neglected diseases. Seminar Briefing. (8). London: Office of Health Economics.
An error has occurred, please try again later.